In late 2017, a study was published in Acta Reumatologica Portuguesa evaluating the effect adalimumab (Humira), an anti–tumor necrosis factor therapy in the treatment of patients with both short- and long-term psoriatic arthritis (PsA) disease duration.
In late 2017, a study was published in Acta Reumatologica Portuguesa evaluating the effect of adalimumab (Humira), an anti—tumor necrosis factor therapy, in the treatment of patients with both short- and long-term psoriatic arthritis (PsA) disease duration.
This study was a multicenter, non-interventional, open cohort trial that utilized data from the Rheumatic Diseases Portuguese Register. Patients included in the study were adults with PsA who were diagnosed according to the Classification Criteria for Psoriatic Arthritis, were registered in the database between June 2008 and June 2016, and had received adalimumab therapy for 3 or more months.
In total, 126 patients were included in the study. Participants with early PsA had a mean disease duration of 2.6 years (±1.3 years) and were significantly younger and began treatment with biologics earlier than patients with late PsA. Conversely, patients with late-stage PsA had a mean disease duration of 13.4 years (±8.1 years).
A Psoriasis Arthritis Response Criteria (PsARC) response was achieved by 72.9% of patients treated with adalimumab at 3 months. Of the participants receiving adalimumab at month 24, 85.4% had a PsARC response. More patients with early PsA achieved PsARC at 3 months than did patients with late PsA (88% versus 62.2%; P =.022) and 24 months (100% versus 75.8%; P =.044).
The early PsA group achieved, on average, a PsARC response 3.8 months after initial treatment with adalimumab; the mean time to PsARC response in patients with late PsA was 7.4 months.
It is important to note that, during the study follow-up, 51 patients (37.8%) discontinued treatment with adalimumab. The mean duration of therapy until discontinuation was 25.7 months (± 21.2 months): 14.7 months (±16.5 months) for patients with early PsA and 29.9 months (± 22.6 months) for those with late PsA (P =.033).
The most common reason for therapy discontinuation was lack of efficacy, and the proportion of patients with early PsA (31.7%) and late PsA (40.0%) who discontinued adalimumab was similar.
Researchers found that, in this real-world clinical setting, patients with PsA who had a shorter disease duration achieved better results after treatment with adalimumab than did patients with a longer disease duration. This finding adds support to the idea that shorter symptom duration and earlier treatment with adalimumab could lead to a more favorable outcome in patients with PsA. Researchers did note, however, that further studies are needed to confirm these results.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.